Medivir names Linda Basse as CMO, adding Darzalex R&D experience to its clinical team

Medivir has named Linda Basse, M.D., Ph.D., as chief medical officer. The appointment puts a leader who played a starring role in the development of Darzalex in charge of ushering Medivir’s clinical pipeline through a critical period.

Basse joins Medivir from Zealand Pharma, where she served as medical director for the past 14 months. But the newly minted CMO is better known for the six years she spent at Genmab. In that time, Basse helped Genmab to bring Johnson & Johnson-partnered cancer drug Darzalex past clinical milestones and onto...